Peking University People's Hospital: Hematology Teams and Research

The department within Peking University hematology

Peking University People's Hospital appears in the Fudan 2023 national hematology specialty reputation list at first place. That is a historical, department-level reputation reference compiled in 2023. It is not a 2026 ranking, it does not rank subspecialties, and it says nothing about which individual clinician would suit a particular patient. Read it as context for why overseas patients and referring doctors ask about this department, not as a selection tool.

The department sits within Peking University's hematology institutional structure, and several of its senior figures also hold university and institute roles. Those academic titles describe research and teaching responsibilities. They do not by themselves confirm outpatient availability, appointment access for international patients, or acceptance into any treatment programme. Separating the institutional reputation from an individual clinical decision is the main practical point of this article.

The documented clinical and research directions

The official university profiles dated June 2025 describe several distinct areas of work. One is leukemia and hematopoietic stem-cell transplantation, including transplant immunology. Another is hematopoietic stem-cell transplantation alongside bleeding and coagulation disorders. A third is clinical and translational research on the bone-marrow microenvironment and hematopoietic regulation. These are different problems with different assessment routes, and a patient's diagnosis will point to one of them rather than to the department as a whole.

Huang Xiaojun's profile describes development of the Beijing Protocol, a non-ex-vivo-T-cell-depleted haploidentical transplantation system, with research on relapse prevention and donor selection. For a patient considering a transplant assessment, this supplies a specific research direction to ask about. It does not establish donor suitability, eligibility or an available treatment place; those questions require the treating transplant team's assessment.

Bleeding and coagulation is a separate direction. Coagulation problems are assessed through a different clinical pathway from leukemia, and the questions a patient needs answered differ accordingly: what the existing records show, what further testing the receiving clinician considers necessary, and whether the condition is one this team manages. Bone-marrow microenvironment work is laboratory and translational research. It may inform how scientists think about blood disease, but a research programme is not a treatment currently established for a particular patient, and patients should not read a publication list as an available therapy.

Huang Xiaojun, Zhang Xiaohui and Kong Yuan

Huang Xiaojun's university profile, dated 20 June 2025, identifies him as a Chinese Academy of Engineering member and Peking University Boya chair professor, as well as director of the Peking University Institute of Hematology and hematology director at Peking University People's Hospital. His listed fields are leukemia, hematopoietic stem-cell transplantation and transplant immunology.

Zhang Xiaohui's profile from the same date identifies him as professor, chief physician, doctoral supervisor and deputy director of the Institute of Hematology. His stated research fields combine hematopoietic stem-cell transplantation with bleeding and coagulation. This is a distinct clinical and academic focus within the broader hematology team.

Kong Yuan is identified as a professor, researcher and doctoral supervisor, and deputy director of a Beijing key laboratory for hematopoietic transplantation in blood disease. Her clinical and translational research concerns the marrow microenvironment and hematopoietic regulation. A laboratory role should be distinguished from an outpatient appointment; the research profile does not establish a patient-facing consultation arrangement.

The wider official hematology and cell therapy roster also includes Zhao Xiangyu, Chang Yingjun, Wang Yu and Tang Feifei. It is useful for understanding the breadth of the academic platform, but not as an appointment timetable. Ask which clinical team would consider the particular diagnosis, rather than assume every listed platform member provides the same service.

What the research means for a patient, and what it does not

Research output matters to patients in indirect ways. It can indicate that a team works continuously on a disease area, that laboratory findings feed into clinical questions, and that transplantation-related problems such as relapse prevention and donor selection are active subjects of study. For a family deciding where to seek an opinion, that context can justify asking a specific question: does this team's documented work relate to my diagnosis, and what would they need to assess it?

It does not answer the questions patients most want answered. A publication does not show that a therapy is available to a new patient, that a clinical trial is open, or that a transplant can proceed. Eligibility review is not enrolment, and a research platform listing is not a treatment offer. Where a patient hopes to join a study, the only reliable answer comes from the study team and the treating clinicians, who must confirm the protocol, the patient's eligibility and the practical arrangements. Similarly, an honor awarded to a clinician recognises past work; it is not a prediction of any individual's outcome.

The practical consequence is to treat research information as a reason to ask better questions rather than as a conclusion. Ask which of the department's documented directions your diagnosis falls under, what records the receiving clinician would need, and what the team would have to confirm before discussing any specific therapy.

Academic distinctions and attributable awards

Huang Xiaojun's academy membership and Boya chair professorship are academic distinctions recorded in his university profile. Zhang Xiaohui's profile lists first-contributor Huaxia Medical Science and Technology First Prize and Chinese Medical Science and Technology Second Prize honors, alongside participation in national science progress awards. These are attributions to a named researcher, not collective awards to every clinician in the department.

Kong Yuan's profile lists publications in Blood, Leukemia and STTT and Huaxia and Chinese medical science honors. The profiles do not supply award years for those prizes, so the article does not add dates. Their relevance is to the documented research fields; an award does not establish access to a therapy or predict the outcome of an individual assessment.

Practical decisions for an overseas patient

The first decision is which question you are actually asking. A new or suspected leukemia diagnosis, a discussion about whether transplantation is an option, a bleeding or clotting problem, and a request for a research opinion are different enquiries with different records. A short summary of the diagnosis, the main question and the key reports is enough to begin; a complete archive is not needed at first contact and should not be sent through an initial web form.

The second decision is what you want from a first step. A records-based specialist opinion while you remain at home is one route, and it is optional rather than a prerequisite for every appointment. A direct appointment request is another. Either way, the hospital and its clinicians decide suitability, acceptance and what further tests are needed; no coordination service can make that decision or promise access to a named clinician, a trial or a transplant.

The third is to prepare specific questions rather than general ones. Ask whether the department's documented work on leukemia, transplantation, coagulation or marrow microenvironment research relates to your diagnosis. Ask which records the receiving clinician would want, whether any language support is available for your appointment, and what the team would need to confirm before discussing a specific therapy. These are questions to put to the provider, because the answers depend on the individual case and on arrangements that this article cannot verify.

How ChinaSpecialistCare can help with this assessment

ChinaSpecialistCare can coordinate a hematology assessment request and help organise records around the question you want answered. We are independent of Peking University People's Hospital. The hospital and its clinicians decide acceptance, clinical suitability and the reviewing team; our coordination does not promise trial enrolment, transplantation or a named expert.

Related specialty reference